Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.78 USD | +9.45% | -1.94% | +107.46% |
03-20 | Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024 | |
03-20 | Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 192M 15.35B |
---|---|---|---|---|---|
Net income 2024 * | -41M -3.28B | Net income 2025 * | -53M -4.24B | EV / Sales 2024 * | - |
Net cash position 2024 * | 116M 9.29B | Net cash position 2025 * | 199M 15.92B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.08
x | P/E ratio 2025 * |
-6.28
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.72% |
Latest transcript on Trevi Therapeutics, Inc.
1 day | +9.45% | ||
1 week | -1.94% | ||
Current month | -19.42% | ||
1 month | -17.99% | ||
3 months | +78.21% | ||
6 months | +57.95% | ||
Current year | +107.46% |
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Good
FOU | Founder | 59 | 28/02/11 |
Thomas Sciascia
FOU | Founder | 70 | 31/12/10 |
Lisa Delfini
DFI | Director of Finance/CFO | 54 | 08/08/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anne VanLent
BRD | Director/Board Member | 76 | 09/10/18 |
James Cassella
BRD | Director/Board Member | 69 | 12/02/20 |
Jennifer Good
FOU | Founder | 59 | 28/02/11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 2.78 | +9.45% | 56,183 |
25/04/24 | 2.54 | -4.15% | 179,237 |
24/04/24 | 2.65 | -7.02% | 124,912 |
23/04/24 | 2.85 | -3.06% | 172,800 |
22/04/24 | 2.94 | +3.70% | 195,512 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.46% | 192M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TRVI Stock